• FluoGuide's stock surged 9.03% today after its Q2 2026 report highlighted significant clinical and regulatory advancements.
  • The company secured FDA authorization for its first U.S. clinical site activation for a pivotal Phase 2 trial (CT-006) in high-grade glioma and reported positive Phase 2 results in oral head and neck cancer.
  • Despite a wider net loss of DKK 12.8 million for Q2 2026, investors focused on the robust progress of its FG001 platform.